President Donald Trump just announced that he was going to be adding more than 600 generic drugs to his federal direct-to-consumer marketplace, TrumpRx. He also said that Cost Plus Drugs—the discount ...

More than 600 generics will be available through the website, Trump said, part of an effort by the administration to expand access to lower-cost medicines. TrumpRx, launched in January, is part of ...

Novo Nordisk has flagged growing generic competition in markets including India as a potential drag on its international business in 2026, highlighting rising pressure on branded obesity and diabetes ...

The most significant addition to the Java language since Sun Microsystems rewrote the collections API for Java 5 is the introduction of Java records. Java records address two significant pain points ...

Type to search articles, cases, and authors. Press ↵ to view all results. Updated on Apr. 30 at 8:35 p.m. Yesterday’s argument in Hikma Pharmaceuticals USA v Amarin Pharma showed a bench once again ...

Java is an object-oriented programming language. To create objects and meaningfully initialize them, a developer must use a Java constructor. Constructors are a critical part of software development ...

Eli Lilly's Mounjaro posted its first monthly sales drop in India in March—a Rs 20-crore decline, from roughly Rs 135 crore in February to Rs 114 crore—just days after a clutch of Indian generics ...

LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

Merck KGaA forecast lackluster earnings in guidance that reflects generic competition for its multiple sclerosis blockbuster drug Mavenclad, but not the potential benefits from the US launch of a ...